These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22269210)
1. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210 [TBL] [Abstract][Full Text] [Related]
2. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825 [TBL] [Abstract][Full Text] [Related]
4. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells. Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957 [TBL] [Abstract][Full Text] [Related]
5. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973 [TBL] [Abstract][Full Text] [Related]
7. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631 [TBL] [Abstract][Full Text] [Related]
8. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264 [TBL] [Abstract][Full Text] [Related]
9. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Tanaka Y; Shibata MA; Morimoto J; Otsuki Y Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369 [TBL] [Abstract][Full Text] [Related]
11. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. Nguyen L; Fifis T; Christophi C BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820 [TBL] [Abstract][Full Text] [Related]
12. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lamszus K; Jin L; Fuchs A; Shi E; Chowdhury S; Yao Y; Polverini PJ; Laterra J; Goldberg ID; Rosen EM Lab Invest; 1997 Mar; 76(3):339-53. PubMed ID: 9121117 [TBL] [Abstract][Full Text] [Related]
13. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy. Chen L; Li C; Zhu Y Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225 [TBL] [Abstract][Full Text] [Related]
14. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152 [TBL] [Abstract][Full Text] [Related]
15. Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Mira A; Morello V; Céspedes MV; Perera T; Comoglio PM; Mangues R; Michieli P Oncotarget; 2017 Jun; 8(24):38193-38213. PubMed ID: 28445144 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388 [TBL] [Abstract][Full Text] [Related]
17. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864 [TBL] [Abstract][Full Text] [Related]
18. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice. Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943 [TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. Bagi CM; Gebhard DF; Andresen CJ Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934 [TBL] [Abstract][Full Text] [Related]
20. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]